Regeneron Pharmaceuticals, Inc., and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

New User Registration
 
 
 
 
 
 
 
 
* Please indicate that you agree to the Terms of Service
*Required field